The British Business Bank has announced a new €58m commitment to a specialist life sciences investment fund as its cumulative backing for UK biotechnology and healthcare businesses reaches £1.13bn.
The commitment to Sofinnova Crossover Fund II will support later-stage life sciences investment, adding to the Bank’s existing participation in specialist funds and direct financing for growing companies.
The British Business Bank has now committed £832m across 20 life sciences investment funds and invested a further £302m directly in 28 scaleups.
Half of the companies receiving direct investment are university spinouts, reflecting the importance of academic research to the UK’s biotechnology industry.
The Bank says its commitments to specialist funds have helped attract £3.1bn in additional private sector investment, equivalent to more than £3 of private capital for every pound committed.
These figures represent accumulated investment activity. The £1.13bn milestone is not a new funding programme of that amount.
The new Sofinnova commitment builds on an earlier investment in the manager’s Sofinnova Capital XI fund and is intended to increase the availability of capital for companies approaching later stages of development.
Funding beyond initial scientific research —
Life sciences businesses often require substantial investment over extended periods before generating commercial revenue.
Drug development, clinical trials, manufacturing processes, and regulatory approvals can all involve significant costs before a product reaches patients or healthcare providers.
The timing of those activities also creates uncertainty for investors. Commercial prospects may depend on clinical trial results or regulatory decisions that cannot be guaranteed when early financing is provided.
Specialist investment funds can help companies secure capital from investors familiar with those risks and the different stages of development involved.
The British Business Bank has been supporting life sciences investment managers for more than a decade, making commitments intended to attract additional private financing into the sector.
Recent activity includes £135m committed across two Advent Life Sciences funds, a £100m cornerstone investment in Apposite Healthcare Growth I, and a $100m commitment to SV Health Investors’ SV8 Biotech Fund.
These investments expand the financial resources available through managers that assess and support specialist healthcare and biotechnology businesses.
The Bank has also developed a direct investment programme, introduced in 2021 to increase the capital available in later-stage funding rounds.
Its direct life sciences commitments now total £302m across 28 companies.
Recent investments include £25m in Alchemab Therapeutics, the Bank’s largest single direct life sciences investment to date.
It has also invested $20m to support Redx Pharma’s development near Manchester and £15m in Cambridge-based university spinout T-Therapeutics.
Those transactions illustrate the range of businesses receiving support as they advance research programmes and seek the capital required for commercial development.
Commercialisation and international investment —
The Bank’s strategy also seeks to increase the availability of UK growth finance for research-led companies that might otherwise depend heavily on overseas capital.
British universities and research institutions generate businesses developing medicines, medical technologies, and specialised healthcare products. Their ability to expand domestically can depend on access to investment beyond the initial stages of company formation.
Recent acquisitions involving companies in the Bank’s investment portfolio demonstrate international demand for some UK life sciences technologies.
In 2024, Merck & Co acquired EyeBio in a transaction potentially worth up to $3bn. Japanese medical technology company Terumo acquired OrganOx for $1.5bn in 2025.
During 2026, university spinout Myricx Bio agreed to be acquired by Novartis in a transaction potentially worth up to $1.5bn.
These are transaction values rather than returns realised by the British Business Bank. Where acquisition values include potential future payments, the full amount is not necessarily received at completion.
Leandros Kalisperas, the Bank’s chief investment officer, has emphasised the need for investment that can support scientific development through lengthy commercialisation processes.
The additional Sofinnova commitment extends that approach, providing further backing for specialist investment management alongside the Bank’s direct equity programme.
The £1.13bn cumulative figure comprises £832m in fund commitments and £302m invested directly in 28 life sciences businesses, while the newly announced €58m commitment strengthens the Bank’s involvement in later-stage funding.




